Radiopharmaceuticals Therapies Market to be Worth USD 27.3 Billion by 2034; Surging Advancements in Technology to Augment Market Expansion

Download Sample

Published Date: December 2024

Radiopharmaceuticals Therapies Market is driven by growing advancements in nuclear medicine and increasing applications of diagnostic and therapeutic sectors. In addition, developments in targeted therapies especially in oncology, and increasing cases of chronic diseases including cancer and cardiovascular diseases are other factors propelling the growth of the global market. Furthermore, technological advancements, such as advanced imaging techniques which increase the efficiency and cost-effectiveness of production are also anticipated to create opportunities for growth of the global market over the forecast period.

Radiopharmaceutical Therapies Market Segmentation Analysis:

By Radioisotope Type	Iodine-131, Gallium-68, Technetium-99m, Zirconium-89, Copper-64, Radium-223, Fluorine-18, Lutetium-177, Rubidium-82, Indium-111, and Others
By Source	Nuclear Reactors, Cyclotrons, and Others
By Application	Oncology, Cardiology, Gastroenterology, Neurology, Nephrology, and Others
By Size Type	Hospitals, Diagnostic Centers, Cancer Research Institutes, Ambulatory Surgical Centers, and Others

Radiopharmaceutical Therapies Market Report Highlights:

In 2023, radiopharmaceuticals therapies market was estimated to be worth USD 15.32 Billion.
By 2034, the target market is expected to grow to USD 27.3 Billion.
Target market is expanding at a CAGR of 6.6%.
North America held the largest share of the market in 2024.
Europe is projected to be the fastest-growing market in the coming years.
By radioisotope type, technetium-99m dominates the target market growth.
By source, cyclotrons is expected to dominate the target market growth.
By application, oncology dominates the target market growth.
By end users, hospitals are expected to dominate the target market growth.

Radiopharmaceutical Therapies Market Dynamics:

Growing Factor	Challenge Factor	Market Trend
High Use in Healthcare Industry	Risk of Radiopharmaceuticals	Technological Advancements

Radiopharmaceutical Therapies Market Key Highlights:

North America: This region is expected to dominate the growth of the market during the forecast period due to a strong healthcare ecosystem, increasing R&D activities, increasing cases of chronic diseases, strong presence of leading pharmaceutical companies, and innovations in technology, among others.

Europe: This region is considered to be the fastest growing region in the target market as due to growing adoption of technological advancements, increasing cases of chronic diseases, increasing demand for novel therapies, and rising investments.

Radiation Therapy Enters the Molecular Age with Radiopharmaceuticals

According to a research study by National Cancer Institute, in October 2020, the treatment of several cancer kinds has changed drastically during the last 20 years. Targeted treatments block particular proteins that aid in the growth, division, and metastasis of cancer cells. Immunotherapies assist combat cancer by either boosting or inhibiting the body's immune system. Radiation therapy, chemotherapy, and surgery are still the mainstays of treatment for the majority of malignancies.

Researchers are now creating a new class of medications known as radiopharmaceuticals that target cancer cells specifically and directly using radiation therapy. Research and clinical studies evaluating novel radiopharmaceuticals have increased significantly in the past few years.

Additionally, radiopharmaceuticals function best when they are able to enter cells. However, that is not a prerequisite for their effectiveness. The radioactive substance in a radiopharmaceutical spontaneously degrades after adhering to a cancer cell. The energy released by this disintegration harms the neighbouring cells' DNA. Additionally, a cell dies when its DNA is irrevocably destroyed. Particularly vulnerable to radiation-induced DNA damage are cancer cells.

Browse ∼52 market data tables and ∼47 figures through ∼189 slides and in-depth TOC on “Radiopharmaceutical Therapies Market Size, Share, By Radioisotope Type (Iodine-131, Gallium-68, Technetium-99m, Zirconium 89, Copper 64, Radium 223, Fluorine 18, Lutetium-177, Rubidium-82, Indium-111, and Others), By Source (Nuclear Reactors, Cyclotrons, and Others), By Application (Oncology, Cardiology, Gastroenterology, Neurology, Nephrology and Others), By End-User (Hospitals, Diagnostic Centers, Cancer Research Institutes, Ambulatory Surgical Centers, and Others), and By Region - Trends, Analysis and Forecast till 2034”

For more insights into the Radiopharmaceuticals Therapies Market and its future trends, visit the link: https://www.prophecymarketinsights.com/market_insight/radiopharmaceutical-therapies-market-5678

Radiopharmaceutical Therapeutics Market Competitive Landscape:

The key players operating in the radiopharmaceuticals therapies market include Bayer AG, Cardinal Health, Eli Lilly and Company, Lantheus, Novartis AG, Bracco, Jubilant Draximage Radiopharmacies, Inc., Eckert & Ziegler, IBA Radiopharma Solutions, Mallinckrodt, NMR, NTP, and PharmaLogic.